[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Definium Therapeutics Inc (DFTX)

Definium Therapeutics Inc (DFTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,181,392
  • Shares Outstanding, K 99,698
  • Annual Sales, $ 0 K
  • Annual Income, $ -183,790 K
  • EBIT $ -166 M
  • EBITDA $ -168 M
  • 60-Month Beta 2.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.09

Options Overview Details

View History
  • Implied Volatility 86.33% (-13.01%)
  • Historical Volatility 54.93%
  • IV Percentile 69%
  • IV Rank 49.31%
  • IV High 111.14% on 03/03/26
  • IV Low 62.19% on 04/15/26
  • Expected Move (DTE 14) 2.47 (11.29%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 153
  • Volume Avg (30-Day) 2,253
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 57,984
  • Open Int (30-Day) 48,464
  • Expected Range 19.38 to 24.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.47
  • Number of Estimates 6
  • High Estimate $-0.39
  • Low Estimate $-0.54
  • Prior Year $-0.35
  • Growth Rate Est. (year over year) -34.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.75 +11.04%
on 04/07/26
26.25 -16.46%
on 04/20/26
+1.33 (+6.46%)
since 04/01/26
3-Month
15.61 +40.44%
on 02/13/26
26.25 -16.46%
on 04/20/26
+5.05 (+29.92%)
since 01/30/26
52-Week
6.03 +263.68%
on 05/09/25
26.25 -16.46%
on 04/20/26
+15.34 (+232.78%)
since 05/01/25

Most Recent Stories

More News
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

DFTX : 21.85 (-0.14%)
These 3 Psychedelic Stocks Activated After Trump's Executive Order

Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.

CMPS : 8.94 (-1.32%)
PSIL : 20.18 (-0.05%)
ATAI : 4.13 (-0.72%)
DFTX : 21.85 (-0.14%)
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing anticipated in 2Q 2026 GAD: Voyage enrollment complete with...

DFTX : 21.85 (-0.14%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

DFTX : 21.85 (-0.14%)
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric...

DFTX : 21.85 (-0.14%)
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

DFTX : 21.85 (-0.14%)
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States

The annual prevalence of newly diagnosed generalized anxiety disorder (GAD) increased from 5.4% in 2020 to 6.6% in 2023 The 3-year total prevalence of GAD reached 10.3%,...

DFTX : 21.85 (-0.14%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

DFTX : 21.85 (-0.14%)
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026

Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological...

DFTX : 21.85 (-0.14%)
Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes...

DFTX : 21.85 (-0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Definium Therapeutics, Inc. is developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Definium Therapeutics Inc., formerly known as Mind Medicine Inc., is based in NEW YORK....

See More

Key Turning Points

3rd Resistance Point 24.19
2nd Resistance Point 23.15
1st Resistance Point 22.51
Last Price 21.85
1st Support Level 20.83
2nd Support Level 19.79
3rd Support Level 19.15

See More

52-Week High 26.25
Last Price 21.85
Fibonacci 61.8% 18.53
Fibonacci 50% 16.14
Fibonacci 38.2% 13.75
52-Week Low 6.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.